Abstract:Low diagnosis rates for Hepatitis C (HCV) mean untreated progressive disease and ongoing infection. Up to 40% of service users on opioid replacement therapy (ORT) from pharmacies are infected. Audit demonstrates that only 2.5% of this estimated population is treated per annum. Stigma, travelling distance, confidentiality concerns and a lack of awareness of how to access testing, have been identified as barriers. For the ORT patients pharmacies offering dried blood spot testing (DBST) may overcome these barriers. This study compares uptake of testing in pharmacies offering DBST with testing from established routes, in a population receiving ORT. Established routes included general practice testing, testing in secondary care, testing in specialist drug services and testing in 3rd sector organisations. A quasi-experimental study design was used to compare non-randomly chosen intervention and control groups for access and uptake of DBST. Staff from 6 community pharmacies were trained to provide DBST and provided with a list of untested patients who could be invited to be tested. The list was constructed through a data linkage exercise joining the prescribing database for Tayside with the laboratory testing database using the community health index number (CHI). The pharmacies tested consenting patients during the last quarter of 2014. The primary outcome measure was the proportion of ORT service users accessing testing. Uptake was compared for patients accessing DBST in the 6 community pharmacies during the last quarter of 2014, compared to service users accessing HCV testing from any other service, for the 12 months of 2014. A total population of 1,339 patients were identified as being prescribed ORT in Dundee City of which 561 had no record of testing for HCV. During the 3 month period, 43 patients from the 6 community pharmacies accepted a DBST from a total of 143 eligible patients attending those pharmacies. Within the 561 eligible patients taking ORT across the whole of Dundee City, 75 patients were tested for HCV (30% Vs 13%). The OR for increased uptake of testing within the 6 pharmacies was 2.25 (95% CI 1.48 to 3.42, Z statistic = 3.81 p = 0.0001). The results from the DBST taken by the pharmacies showed 12 patients HCV+, 23 HCV negative, 7 DBSTs were not processed because of a missing ID number and 1 sample was a duplicate. This initial evaluation of DBST in community pharmacies found that a greater proportion of ORT service users took up the offer of a test, compared to the offer of a test from a wider range of providers, over a longer time period. This study shows that DBST in community pharmacies is both a feasible and effective method. None Declared.

Testing, diagnosis, and treatment following the implementation of a program to provide dried blood spot testing for HIV and hepatitis C infections: the NSW DBS Pilot

PTU-095 Dried blood spot testing for hepatitis C in community pharmacy – interim reporting of a quasi-experimental study of effectiveness

Dried blood spot sampling as an alternative for the improvement of hepatitis B and C diagnosis in key populations

Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey

Laboratory-based dried blood spot testing for hepatitis C: A protocol for systematic review and meta-analysis of diagnostic accuracy

Client and staff perceptions of acceptability of MyCheck: a direct-to-pathology telehealth and e-testing service for comprehensive bloodborne virus and sexually transmissible infection screening

Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study

Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia

Pilot postal birth cohort HCV Screening in UK primary care

Point of care testing for hepatitis C in the priority settings of mental health, prisons and drug & alcohol facilities – the PROMPt Study

'Just another vial…': a qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK

VirA+EmiC project: Evaluating real‐world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department

Patient and healthcare provider perceptions of acceptability of fingerstick point-of-care hepatitis C testing at Aboriginal Community Controlled Health Services in Australia

Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019

A pilot project harnessing surveillance systems to support clinicians providing clinical care for people diagnosed with hepatitis C in Victoria, Australia, September 2021 to 31 March 2022

Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study

Validation of dried blood spots for capturing hepatitis C virus diversity for genomic surveillance

I was like sh*t this is gonna hurt': Implementing Self-Sampling of Dried Blood Spots to Measure HIV Viral Load

Findings from a Project Which Established Hepatitis C Point-of-Care Testing and Linkage to Care at a Homelessness Service in Adelaide, Australia, 2021–2022

Development and acceptability of a digital tool for promoting syphilis testing in Australian general practice: qualitative study using the Theoretical Framework of Acceptability

Uptake of guideline-based testing for chronic viral hepatitis in Australian primary care: retrospective analysis of electronic medical record data